Tranzone secures GSK deal
Will store various products in Jebel Ali for distribution to the Gulf and Near East Region
The deal was signed during the opening ceremony for Tranzone’s new facility.
GSK will occupy a major part of Tranzone’s warehouse, contributing approximately 25% of revenue in 2012.
Tranzone said GSK had demanded top-of-the-range facilities and back up to protect products at all times and in all circumstances. Emphasis had also been placed on physical security such as access control and fire prevention and process quality.
Tranzone’s state-of-the-art 3PL warehouse at JAFZA in Jebel Ali provides storage, inventory management, as well as purchasing and re-invoicing to the distributor, all at one convenient location. The firm says it is able to store pharmaceuticals in an ideal environment, and its integrated system better links principals with distributors, removes layers of inefficiency and cuts costs while improving service quality.
You may also like
Trending Articles
You may also like
Logistics
![Imara Sickle Cell Framework launches to coordinate diagnosis-to-treatment care across Africa]()
Imara Sickle Cell Framework launches to coordinate diagnosis-to-treatment care across Africa
Initial implementation begins in Uganda, Kenya and Côte d'Ivoire, connecting screening, diagnosis, referral and long-term management into a unified pathway as the continent accounts for nearly 80% of the global disease burden
Finance
![Aplagon closes €4.8m round to advance first-in-class antithrombotic APAC into Phase II AVF trial]()
Aplagon closes €4.8m round to advance first-in-class antithrombotic APAC into Phase II AVF trial
The financing supports a European CTA filing with the EMA for arteriovenous fistula maturation failure in end-stage kidney disease, expanding APAC's clinical programme across thrombo-inflammatory indications
Manufacturing
![AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn]()
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance
![GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors]()
GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors
GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer